ProPhase launches Cold-Eeze oral spray

DOYLESTOWN, Pa. — ProPhase Labs on Tuesday launched the Cold-Eeze oral spray, which is formulated with zinc gluconate to help reduce the severity and duration of the common cold.

"Our Cold-Eeze oral spray is a new opportunity to provide relief to our consumers in a new delivery system," stated Ted Karkus, chairman and CEO of ProPhase. "Our lozenges have always been a leader in the over-the-counter cough-and-cold category, and we saw Cold-Eeze oral spray as the logical next step in offering our consumers variety and alternatives to the traditional lozenge to help them reduce the severity and duration of their colds."

Two sprays offer the same amount of cold remedy (active ingredient zinc gluconate) as one Cold-Eeze lozenge, the company stated.

Available in cherry and mint flavors, each 13.3-mg bottle contains at least 45 doses.

 


Interested in this topic? Sign up for our weekly Retail Health Provider e-newsletter.